Prior antiretroviral therapy experience protects against zidovudine-related anaemia
Prior antiretroviral therapy experience protects against zidovudine-related anaemia
复制标题
DOI：
10.1111/j.1468-1293.2007.00498.x
复制
发表时间：
2007-10-01
期刊：
影响因子：
3
通讯作者：
Ditangco, R.
中科院分区：
文献类型：
--
作者：
Huffam, S. E.;Srasuebkul, P.;Ditangco, R.
目的我们利用来自 TREAT Asia HIV 观察数据库 (TAHOD) 的数据，调查了含有齐多夫定或司他夫定的抗逆转录病毒治疗方案的使用情况，该数据库是一项针对亚太地区 HIV 感染队列的多中心、前瞻性、观察性研究。在初始或随后的治疗方案中开始齐多夫定后 6 个月内进行贫血。结果开始使用齐多夫定的患者比开始使用司他夫定的患者更有可能在治疗的前 9 个月内停止治疗； 9个月后情况正好相反。贫血（血红蛋白
ObjectiveWe investigated the use of antiretroviral therapy regimens containing zidovudine or stavudine, using data from the TREAT Asia HIV Observational Database (TAHOD), a multicentre, prospective, observational study of an HIV-infected cohort in the Asia-Pacific Region.MethodsA proportional hazards regression analysis of factors associated with the time to discontinuation of initial regimens containing zidovudine or stavudine and a logistic regression analysis to identify factors associated with a diagnosis of anaemia within 6 months of commencement of zidovudine in initial or subsequent regimens were performed.ResultsPatients who started zidovudine were more likely to stop within the first 9 months of treatment than those who started on stavudine; the reverse was true after 9 months. Anaemia (haemoglobin